Emerging Company Profile

Article


<div class="articleContainer">
<div class="articleWrapper">
<div class="articleContent">
<h1 class="text title" doc-editable="text" data-component-id="doc-1fh3me1dm0">TenSixteen: Targeting dynamic genome to find driver mutations, catch cancer earlier&#xA0;</h1><h2 class="title-bottom webtitle" doc-editable="title" data-component-id="doc-1fh3men3r0">Foresite, <a href="https://profiles.biocentury.com/companies/gv">GV</a> lead $40M A round to build data platform, Dx assay</h2><div class="byline ng-tns-c17-4 ng-star-inserted" data-component-id="doc-1fh3me7lj0">
    <span class="ng-tns-c17-4" doc-editable="text">By Stephen Hansen, Associate Editor</span>
</div><div class="date" data-component-id="doc-1fh3mec8j0">
  <span class="byline" doc-editable="text"></span>
</div></div></div></div>


Foresite Capital

TenSixteen Bio Inc.

Cancer

Myelodysplastic syndrome (MDS)

Tet methylcytosine dioxygenase 2 (TET2)

Additional sex combs like 1 (ASXL1)

DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A)

TenSixteen: Targeting dynamic genome to find driver mutations, catch cancer earlier 

Foresite, GV lead $40M A round to build data platform, Dx assay

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>